Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ZyVersa Therapeutics, Inc. - Common Stock
(NQ:
ZVSA
)
4.290
-0.120 (-2.72%)
Streaming Delayed Price
Updated: 10:55 AM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ZyVersa Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200’s Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease
October 11, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues
October 04, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
September 27, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
September 22, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
September 12, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results
August 21, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
July 24, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
July 17, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023
July 14, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
July 10, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
July 07, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity
June 28, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)
June 20, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target
June 13, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
June 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis
May 25, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Changes to ZyVersa’s Board of Directors
May 19, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease
May 15, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
May 12, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.’s Virtual Healthcare Conference
May 11, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention
May 09, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
May 04, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
May 01, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference
April 27, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public Offering
April 26, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
April 25, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100
April 24, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV
April 24, 2023
Via
ACCESSWIRE
ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants
April 19, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease
April 13, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.